Valuation : Galapagos NV

Market Cap 1.55B 1.8B 1.8B 1.46B 1.33B 2.49B 172B 2.5B 17.32B 6.69B 87.42B 6.77B 6.62B 277B P/E 2026 *
-14x
P/E 2027 * -4.78x
Enterprise Value -879M -1.02B -1.02B -827M -754M -1.41B -97.17B -1.42B -9.81B -3.79B -49.5B -3.83B -3.75B -157B EV / Sales 2026 *
-9.26x
EV / Sales 2027 * 0.49x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-11
Director of Finance/CFO 41 2025-07-06
Chief Operating Officer - 2026-05-31
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-11
Change 5-day change 1-year change 3-year change Capi.($)
-3.24%-7.78%-5.35%+11.20% 46.38B
+0.17%-0.74%+407.28%+546.58% 44.51B
-0.86%-2.60%+35.51%+20.35% 42.3B
-0.14%-2.98%-0.04%+82.21% 39.91B
0.00%-1.72%+13.42%+42.33% 32.79B
-3.44%-2.43% - - 17.13B
-0.78%-1.13%+20.74%+116.26% 16.36B
-0.37%-2.53%+10.91%+30.93% 14.31B
-0.86%-4.60%+76.86%+39.36% 13.29B
Average -1.06%-2.88%+69.92%+111.15% 29.66B
Weighted average by Cap. -1.02%-3.04%+85.41%+133.07%

Financials

2026 *2027 *
Net sales 94.87M 110M 110M 89.32M 81.39M 152M 10.49B 153M 1.06B 409M 5.34B 414M 405M 16.93B 80.29M 93.31M 93.31M 75.6M 68.89M 129M 8.88B 129M 896M 346M 4.52B 350M 343M 14.33B
Net income -40.7M -47.29M -47.29M -38.32M -34.91M -65.33M -4.5B -65.59M -454M -176M -2.29B -178M -174M -7.26B -213M -247M -247M -200M -182M -341M -23.52B -343M -2.37B -917M -11.98B -928M -908M -37.96B
Net Debt -2.43B -2.82B -2.82B -2.29B -2.09B -3.9B -269B -3.92B -27.12B -10.48B -137B -10.61B -10.38B -434B -1.51B -1.76B -1.76B -1.42B -1.3B -2.43B -167B -2.44B -16.88B -6.52B -85.2B -6.6B -6.46B -270B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!